Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Low-dose Everolimus Group	277
Overall Study	STARTED	High-dose Everolimus Group	279
Overall Study	STARTED	Control Group	277
Overall Study	12 Month Analysis	Low-dose Everolimus Group	241
Overall Study	12 Month Analysis	High-dose Everolimus Group	249
Overall Study	12 Month Analysis	Control Group	253
Overall Study	24 Month Analysis	Low-dose Everolimus Group	232
Overall Study	24 Month Analysis	High-dose Everolimus Group	238
Overall Study	24 Month Analysis	Control Group	246
Overall Study	COMPLETED	Low-dose Everolimus Group	232
Overall Study	COMPLETED	High-dose Everolimus Group	238
Overall Study	COMPLETED	Control Group	246
Overall Study	NOT COMPLETED	Low-dose Everolimus Group	45
Overall Study	NOT COMPLETED	High-dose Everolimus Group	41
Overall Study	NOT COMPLETED	Control Group	31

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00251004/flow